Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Zogenix (ZGNX) today and set a price target of $60. The company’s shares closed on Friday at $47.78.
According to TipRanks.com, Higgins is ranked 0 out of 5 stars with an average return of -6.9% and a 32.0% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Armata Pharmaceuticals Inc, Rhythm Pharmaceuticals Inc, and Achieve Life Sciences Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zogenix with a $61.38 average price target, which is a 28.5% upside from current levels. In a report issued on June 27, Guggenheim also upgraded the stock to Buy with a $64 price target.
See today’s analyst top recommended stocks >>
Based on Zogenix’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $35.2 million. In comparison, last year the company had a GAAP net loss of $29.04 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Zogenix, Inc. is a pharmaceutical compan. It engages in the development and commercialization of central nervous system (CNS) therapies and products for the treatment orphan diseases and other CNS disorders. Its products include ZX008 and Relday.
